Drugs for functional gastrointestinal disorders
Drotaverine-Darnitsa is an isoquinoline derivative that exerts antispasmodic action on smooth muscle via inhibition of phosphodiesterase–4 (PDE4), resulting in an increase in the cAMP concentration and leading to smooth muscle relaxation due to inactivation of the myosin light chain kinase (MLCK). In vitro, drotaverine suppresses the action of PDE4 and inhibits isoenzymes phosphodiesterase-3 (PDE3) and phosphodiesterase-5 (PDE5).
For the treatment of:
– Smooth muscle spasms in the biliary tract diseases: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis
– Smooth muscle spasms in the urinary tract diseases: nephrolithiasis, urethrolithiasis, pyelitis, cystitis, vesical tenesmus
As an adjuvant treatment in:
– Smooth muscle spasms in the gastrointestinal tract diseases: gastric and duodenal ulcers, gastritis, cardio- and/or pylorospasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome with flatulence
– Stress headache
– Gynecological diseases (dysmenorrhea)
Drotaverine-Darnitsa is intended for internal use.
Adults: the average daily dose is 120–240 mg (3–6 tablets) divided into 2–3 doses.
Children aged 6–12 years: the maximum daily dose is 80 mg divided into 2 doses.
Children aged over 12 years: the maximum daily dose is 160 mg divided into 2–4 doses.
The duration of the treatment course should be determined on an individual basis.